The inflammatory bowel disease market is expected to reach $21.4 billion by 2024 from the existing $18.4 billion in 2019 A graphic accompanying this announcement is ...
LOS ANGELES, March 06, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical ...
100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trial IMX-110 is in clinical development as a ...
LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We ...
ImmixBio: IMX-110 Shows Improved Survival In Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
(RTTNews) - Immix Biopharma Inc. (IMMX) announced positive interim study data showing that after one cycle of treatment, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for ...
LOS ANGELES, Aug. 17, 2021 /PRNewswire/ -- Immix Biopharma, Inc. ("ImmixBio"), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx) ™ for oncology and inflammation, today announced ...
Tislelizumab supplied by BeiGene as part of ImmixBio’s Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors IMX-110 + Tislelizumab ...
LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company with a market capitalization of $79.38 million, announced Wednesday that it plans to seek external ...
LOS ANGELES, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “we” or “us”), a biopharmaceutical company ...
IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cells ImmixBio anticipates filing an IND for IMX-120 in 2023 The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results